Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas van As

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Practical Radiation Oncology|November 22, 2014
Intensity modulated radiation therapy allows prostate and dose-escalated pelvic radical radiation therapy after renal transplantationNicola Rosenfelder, Richard Corbett, Michelle Long, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 12, 2023
Interobserver variation in clinical target volume (CTV) delineation for stereotactic radiotherapy to non-spinal bone metastases in prostate cancer: CT, MRI and PET/CT fusionEwan Richard Chapman, Luke Nicholls, Yae-Eun Suh, et al.
Clinical and Translational Radiation Oncology|November 4, 2020
Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trialLuke Nicholls, Yae-Eun Suh, Ewan Chapman, et al.
Clinical and Translational Radiation Oncology|April 8, 2024
Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicityRagu Ratnakumaran, Jonathan Mohajer, Samuel J Withey, et al.
BJU International|November 8, 2008
Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling timeMichael K Ng, Nicholas Van As, Karen Thomas, et al.
International Journal of Radiation Oncology, Biology, Physics|December 1, 2025
Predictors of Long-Term Disease-Free Survival With Stereotactic Body Radiation Therapy for Oligometastatic Prostate CancerBinnaz Yasar, Ewan Chapman, Helen Taylor, et al.
European Urology|October 23, 2025
Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B StudyRagu Ratnakumaran, Douglas H Brand, Archana Sasitharan, et al.
CA: a Cancer Journal for Clinicians|June 27, 2025
The contemporary management of prostate cancerDeep Chakrabarti, Peter Albertsen, Aidan Adkins, et al.
Clinical and Translational Radiation Oncology|June 14, 2024
Weekly ultra-hypofractionated radiotherapy in localised prostate cancerNora Sundahl, Douglas Brand, Chris Parker, et al.
International Journal of Radiation Oncology, Biology, Physics|January 25, 2025
Dosimetric Comparison of CyberKnife and Conventional Linac Prostate Stereotactic Body Radiation Therapy Plans: Analysis of the PACE-B StudyRagu Ratnakumaran, Archana Sasitharan, Asadullah Khan, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Practical Radiation Oncology|November 22, 2014
Intensity modulated radiation therapy allows prostate and dose-escalated pelvic radical radiation therapy after renal transplantationNicola Rosenfelder, Richard Corbett, Michelle Long, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 12, 2023
Interobserver variation in clinical target volume (CTV) delineation for stereotactic radiotherapy to non-spinal bone metastases in prostate cancer: CT, MRI and PET/CT fusionEwan Richard Chapman, Luke Nicholls, Yae-Eun Suh, et al.
Clinical and Translational Radiation Oncology|November 4, 2020
Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trialLuke Nicholls, Yae-Eun Suh, Ewan Chapman, et al.
Clinical and Translational Radiation Oncology|April 8, 2024
Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicityRagu Ratnakumaran, Jonathan Mohajer, Samuel J Withey, et al.
BJU International|November 8, 2008
Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling timeMichael K Ng, Nicholas Van As, Karen Thomas, et al.
International Journal of Radiation Oncology, Biology, Physics|December 1, 2025
Predictors of Long-Term Disease-Free Survival With Stereotactic Body Radiation Therapy for Oligometastatic Prostate CancerBinnaz Yasar, Ewan Chapman, Helen Taylor, et al.
European Urology|October 23, 2025
Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B StudyRagu Ratnakumaran, Douglas H Brand, Archana Sasitharan, et al.
CA: a Cancer Journal for Clinicians|June 27, 2025
The contemporary management of prostate cancerDeep Chakrabarti, Peter Albertsen, Aidan Adkins, et al.
Clinical and Translational Radiation Oncology|June 14, 2024
Weekly ultra-hypofractionated radiotherapy in localised prostate cancerNora Sundahl, Douglas Brand, Chris Parker, et al.
International Journal of Radiation Oncology, Biology, Physics|January 25, 2025
Dosimetric Comparison of CyberKnife and Conventional Linac Prostate Stereotactic Body Radiation Therapy Plans: Analysis of the PACE-B StudyRagu Ratnakumaran, Archana Sasitharan, Asadullah Khan, et al.
Pageof 6